At last check, the Mind Medicine stock is up 3.16 percent in premarket trading and could continue to rise as researchers look at the effects of LSD on anxiety, pain, and adult ADHD.
Full Answer
Should you buy Mind Medicine (mindmed) stock?
The consensus among Wall Street research analysts is that investors should "buy" Mind Medicine (MindMed) stock. View analyst ratings for Mind Medicine (MindMed) or view top-rated stocks. What stocks does MarketBeat like better than Mind Medicine (MindMed)?
What are the signals in the Mind Medicine stock?
There are mixed signals in the stock today. The Mind Medicine (MindMed) Inc. Subordinatestock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
What is the price of Mind Medicine (mmedf) stock?
Since then, MMEDF shares have increased by 257.1% and is now trading at $1.25. View which stocks have been most impacted by COVID-19. Who are Mind Medicine (MindMed)'s key executives?
What is the latest on the mindmed IND?
The previously announced clinical hold on the IND was lifted following MindMed’s responses for additional information related to the participant monitoring protocol in the upcoming study. Participant enrollment for the study is expected to start in early 2022.
How has Mind Medicine (MindMed)'s stock performed in 2022?
Mind Medicine (MindMed)'s stock was trading at $1.38 at the beginning of 2022. Since then, MMEDF shares have decreased by 42.0% and is now trading...
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people: Mr. Jamon Alexander Rahn , Co-Founder, CEO & Director Dr. Miriam Halperi...
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include 3SBio (TRSBF) , 45525 (CUR.TO) (CUR) , Abattis Bioceuticals (ATTBF) , Abcam...
What is Mind Medicine (MindMed)'s stock symbol?
Mind Medicine (MindMed) trades on the OTCMKTS under the ticker symbol "MMEDF."
How do I buy shares of Mind Medicine (MindMed)?
Shares of MMEDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Mind Medicine (MindMed)'s stock price today?
One share of MMEDF stock can currently be purchased for approximately $0.80.
How many employees does Mind Medicine (MindMed) have?
Mind Medicine (MindMed) employs 22 workers across the globe.
What is Mind Medicine (MindMed)'s official website?
The official website for Mind Medicine (MindMed) is www.mindmed.co .
Q2 Financial Results 2021
As of June 30, 2021, the company’s total assets were $194 million, including $157 million in cash. For the quarter ended June 30, 2021, net cash used in operating activities was $12 million. For the quarter ending June 30, 2021, there was a net and comprehensive loss of $36 million.
Sphere Health and MindMed have announced a strategic research collaboration
Sphere Health, a physician-founded employee benefits provider focused on treatments for people with severe mental illness, has agreed to collaborate with a leading biotech company developing psychedelic-inspired therapies to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses such as anxiety and affective disorders..
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
Headlines
UPDATE: Maxim Group On Mind Medicine: Firm Believes Co. Has 'One Of The Most Diverse Pipelines In Psychedelics' With $160M In Cash.
Mind Medicine (MindMed) (OTCMKTS:MMEDF) Frequently Asked Questions
Mind Medicine (MindMed)'s stock was trading at $0.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MMEDF shares have increased by 245.7% and is now trading at $1.21. View which stocks have been most impacted by COVID-19.
What is MindMed on the NASDAQ?
In a long-awaited move, psychedelic therapy developer Mind Medicine (or MindMed) ( NASDAQ:MNMD) was registered on the NASDAQ on Tuesday of last week, causing its stock to explode by more than 50% compared to its level earlier in the month.
What is the Phase 2b of MindMed?
Perhaps the most important catalysts for shareholders are the company's three headliner pipeline projects in phase 2 trials. Two of these projects seek to treat conditions like attention deficit hyperactivity disorder (ADHD) and anxiety using LSD, whereas the third is an investigational treatment for addiction using a compound containing ibogaine, a naturally occurring psychoactive found in certain plants. Phase 2b of the LSD-for-anxiety trial will start sometime in Q4. Before that, MindMed will need to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA), so investors can expect an appreciable bump in stock price if regulators assent to the trial.
Can MDMA be optimized?
The data confirms that "the dose of MDMA can be optimized using predictors [such as] body weight, sex, age, genetics, personality trait measures, and mood before drug administration.". If you're a pharmacologist or medical professional, that finding might seem a bit obvious.